Patents by Inventor Zhoufeng Chen

Zhoufeng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11252121
    Abstract: Embodiments of the disclosure provide methods and devices for sending messages. The method can include: storing identifiers corresponding to one or more messages that are to be sent in a first message identifier queue; storing identifiers corresponding to one or more messages that are being sent in a second message identifier queue; acquiring an identifier corresponding to a message in the first message identifier queue; moving the identifier to the second message identifier queue; and sending the message according to a sending order associated with the identifier in the second message identifier queue.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 15, 2022
    Assignee: ALIBABA GROUP HOLDING LIMITED
    Inventors: Jianfeng Chen, Pan Zeng, Hui Chen, Zhoufeng Chen
  • Patent number: 11165740
    Abstract: Embodiments of the present disclosure provide to a message management method and apparatus. The message management method includes: recording, in a memory, a number range of consumable messages in a message queue, wherein the number range includes numberings of the consumable messages; and adjusting the number range and managing the messages according to status changes of the messages in the message queue.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 2, 2021
    Assignee: Alibaba Group Holding Limited
    Inventors: Jianfeng Chen, Qiang Lin, Zhoufeng Chen
  • Publication number: 20190028422
    Abstract: Embodiments of the present disclosure provide to a message management method and apparatus. The message management method includes: recording, in a memory, a number range of consumable messages in a message queue, wherein the number range includes numberings of the consumable messages; and adjusting the number range and managing the messages according to status changes of the messages in the message queue.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Inventors: Jianfeng CHEN, Qiang LIN, Zhoufeng CHEN
  • Publication number: 20190028420
    Abstract: Embodiments of the disclosure provide methods and devices for sending messages. The method can include: storing identifiers corresponding to one or more messages that are to be sent in a first message identifier queue; storing identifiers corresponding to one or more messages that are being sent in a second message identifier queue; acquiring an identifier corresponding to a message in the first message identifier queue; moving the identifier to the second message identifier queue; and sending the message according to a sending order associated with the identifier in the second message identifier queue.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Inventors: Jianfeng CHEN, Pan ZENG, Hui CHEN, Zhoufeng CHEN
  • Publication number: 20140351960
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Application
    Filed: November 22, 2013
    Publication date: November 27, 2014
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Publication number: 20130091591
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Application
    Filed: August 29, 2012
    Publication date: April 11, 2013
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Publication number: 20110195901
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Application
    Filed: April 1, 2011
    Publication date: August 11, 2011
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 7939071
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: May 10, 2011
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 7741272
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: June 22, 2010
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Publication number: 20100130419
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Application
    Filed: September 25, 2009
    Publication date: May 27, 2010
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: HAI U. WANG, ZHOUFENG CHEN, DAVID J. ANDERSON
  • Patent number: 7700297
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 20, 2010
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 7595044
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: September 29, 2009
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Publication number: 20060288434
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Application
    Filed: January 4, 2005
    Publication date: December 21, 2006
    Applicant: California Institute of Technology
    Inventors: Hai Wang, Zhoufeng Chen, David Anderson
  • Publication number: 20060035328
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Application
    Filed: July 15, 2005
    Publication date: February 16, 2006
    Applicant: California Institute of Technology
    Inventors: Hai Wang, Zhoufeng Chen, David Anderson
  • Publication number: 20050204412
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Application
    Filed: February 18, 2005
    Publication date: September 15, 2005
    Applicant: California Institute of Technology
    Inventors: Hai Wang, Zhoufeng Chen, David Anderson
  • Patent number: 6916625
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: July 12, 2005
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 6887674
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 3, 2005
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 6864227
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: March 8, 2005
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Publication number: 20030207447
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Application
    Filed: June 10, 2003
    Publication date: November 6, 2003
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
  • Patent number: 6579683
    Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: June 17, 2003
    Assignee: California Institute of Technology
    Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson